For organ transplant patients, there is a rejection reaction after surgery, that is, immune cells (mainly T cells) in the body attack the implanted organs. Patients need to take immunosuppressive agents for a long time to inhibit T cell activation caused by organ transplantation. The reporter learned from the Nanjing Medical University on the 22nd that the research team of the school designed a "smart" supramolecular hydrogel, which can "smart" the release of immunosuppressive drugs according to the patient's immune status. This achievement was recently published in the international academic journal Advanced Materials.
After the general liver transplant patients are discharged from hospital, the drug cost in the first year is as high as 200,000 yuan, and will be reduced year by year, but at least 50,000 yuan/year. Long-term use of immunosuppressive agents is not only expensive, but patients are also prone to complications such as new tumors after transplantation, new diabetes after transplantation, hyperlipidemia, hyperuricemia, cardiovascular and cerebrovascular diseases. In addition, some patients have more serious rejection reactions, and more immunosuppressive agents are needed. Some patients have better tolerance and less rejection. Taking too much medicine is not only wasteful, but also harmful to the body.
Under the guidance of Academician Wang Xuehao of Nanjing Medical University, Wu Jindao Research Team of Nanyi First Affiliated Hospital cooperated with Wang Fuqiang technical team of Nanfang Medical Analysis and Testing Center to design a “smart†supramolecular hydrogel. It acts like a "switch" in the body. When the rejection is severe, the activity of phosphorylated kinase (PTK) is high; when the rejection is light, its activity is low. Based on this, when the PTK activity is high, the hydrophilicity of the supramolecular hydrogel is enhanced, so that the supramolecular degumming releases the drug, and when the PTK activity is low, the supramolecular hydrogel maintains the colloidal property, and the drug stops releasing.
"The advantage of this strategy is that it can be personalized and accurately administered, according to the patient's disease level, intelligent release of drugs, the same patient in different disease periods, the amount of drug released is also different, thus avoiding the side effects of long-term use of immunosuppressants." Wang Fuqiang, executive deputy director of the Analysis and Testing Center, said.
According to this method, the patient can be changed from the original twice daily medication to the hydrogel once every half month, and the side effects are basically disappeared. (Reporter Zhang Wei)
Source: Technology Daily
Heavy Biometric Safe Box,Double Door Safe Box,Combination Safe Box,Customizable Safe Box
Hebei Yingbo Safe Boxes Co.,Ltd , https://www.yingbosafebox.com